Menu
Back to Journals » Cancer Management and Research » Volume 11
Systemic inflammation response index predicts prognosis in patients with clear cell renal cell carcinoma: a propensity score-matched analysis
Authors Chen Z, Wang K, Lu H, Xue D, Fan M, Zhuang Q, Yin S, He X, Xu R
Received 9 September 2018
Accepted for publication 28 November 2018
Published 18 January 2019 Volume 2019:11 Pages 909—919
DOI https://doi.org/10.2147/CMAR.S186976
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Dr Chien-Feng Li
Zhen Chen,* Kai Wang,* Hao Lu, Dong Xue, Min Fan, Qianfeng Zhuang, Shuai Yin, Xiaozhou He, Renfang Xu
Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, People’s Republic of China
*These authors contributed equally to this work
Purpose: In the present study, we aimed to evaluate the prognostic significance of the systemic inflammation response index (SIRI), which was defined based on peripheral blood counts of neutrophils, lymphocytes, and monocytes, in patients with localized or locally advanced clear cell renal cell carcinoma (CCRCC).
Patients and methods: The prognostic value of SIRI was evaluated in a primary cohort consisting of 414 patients with localized or locally advanced CCRCC and then further validated in an independent cohort composed of 168 patients.
Results: Kaplan–Meier survival analyses of both cohorts revealed that CCRCC patients with high SIRI levels exhibited poorer overall survival (OS) and cancer-specific survival (CSS) compared with those with low SIRI levels. Furthermore, univariate and multivariate analyses identified SIRI as a significant independent predictor for both OS (HR: 4.853; 95% CI: 2.362–9.972; P<0.001) and CSS (HR: 5.913; 95% CI: 2.681–13.040; P<0.001). Following propensity score matching analysis, SIRI remained an excellent predictor for both OS and CSS. The area under the curve for SIRI was larger than that of the platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic score in both cohorts.
Conclusion: SIRI might be a better prognostic predictor than PLR, NLR, MLR, and MSKCC score in patients with localized or locally advanced CCRCC.
Institutional review board approval number: (2010) Scientific Research Project No. 39
Keywords: systemic inflammation response index, prognosis, clear cell renal cell carcinoma, PSM
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.